We observed a strong correlation between the genome-wide DNA methylation status (GWMS) and the clinical outcomes of anti-EGFR antibodies, and we found that high-methylated colorectal cancer (HMCC) was refractory to anti-EGFR antibodies compared with low-methylated colorectal cancer (LMCC). This evidence concerns the gene EGFR and colorectal cancer.